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Abstract
Background: Autophagy mediates lysosomal degradation of cytosolic components. Recent work has associated
autophagic dysfunction with pathologies, including cancer and cardiovascular disease. To date, the identification of
clinically-applicable drugs that modulate autophagy has been hampered by the lack of standardized assays capable
of precisely reporting autophagic activity.
Results: We developed and implemented a high-content, flow-cytometry-based screening approach for rapid,
precise, and quantitative measurements of pharmaceutical control over autophagy. Our assay allowed for time-
resolved individual measurements of autolysosome formation and degradation, and endolysosomal activities under
both basal and activated autophagy conditions. As proof of concept, we analyzed conventional autophagy
regulators, including cardioprotective compounds aminoimidazole carboxamide ribonucleotide (AICAR), rapamycin,
and resveratrol, and revealed striking conditional dependencies of rapamycin and autophagy inhibitor 3-
methyladenine (3-MA). To identify novel autophagy modulators with translational potential, we screened the
Prestwick Chemical Library of 1,120 US Food and Drug Administration (FDA)-approved compounds for impact on
autolysosome formation. In all, 38 compounds were identified as potential activators, and 36 as potential inhibitors
of autophagy. Notably, amongst the autophagy enhancers were cardiac glycosides, from which we selected
digoxin, strophanthidin, and digoxigenin for validation by standard biochemical and imaging techniques. We
report the induction of autophagic flux by these cardiac glycosides, and the concentrations allowing for specific
enhancement of autophagic activities without impact on endolysosomal activities.
Conclusions: Our systematic analysis of autophagic and endolysosomal activities outperformed conventional
autophagy assays and highlights the complexity of drug influence on autophagy. We demonstrate conditional
dependencies of established regulators. Moreover, we identified new autophagy regulators and characterized
cardiac glycosides as novel potent inducers of autophagic flux.
Background
Macroautophagy (hereafter referred to as autophagy),
the process of cytoplasmic component degradation via
lysosomes, has a multifaceted involvement in human
disease, including neurodegeneration, viral and bacterial
infections, heart disease, and cancer [1,2]. Positive and
negative control of autophagic activity is distributed
among signaling pathways involved in a wide range of
stress and survival responses [3-5]. Intriguingly, com-
pounds activating autophagy via the AMP-activated pro-
tein kinase (AMPK)/mammalian target of rapamycin
(mTOR) pathway, including resveratrol and rapamycin,
exert protective effects in models of cardiovascular dis-
ease, but cytotoxic or cytostatic effects in cancer models
[6-8]. Given its high degree of integration into major
cell signaling pathways, autophagy represents an attrac-
tive target for pharmaceutical manipulation.
Autophagy is a dynamic process which can be classi-
fied into three discrete stages: (1) sequestration of cyto-
solic components by the autophagosome, (2) fusion of
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autolysosome, and (3) degradation of autophagosomal
contents by proteases within the lysosome. Moreover,
t h ee n d o s o m a lp a t h w a yi sh i g h l yi n t e g r a t e di n t ot h e
autophagosomal and lysosomal pathways. Late endo-
somes undergo fusion with lysosomes and autophago-
somes [9], and the endosomal sorting complexes
mediate autolysosome formation [10-12].
High-content screening for the identification of small
compounds to regulate autophagy is limited by the lack
of methods to specifically quantify each step of the
autophagy process. This, however, is the prerequisite for
the robust interpretation of autophagic activity. Recent
studies utilized fluorescence detection of green fluores-
cent protein-microtubule-associated protein 1 light
chain 3 B (GFP-LC3) vesicles [13,14], specific autophagy
substrates [15], or luciferase-based assays [16] for infer-
ring activities. However, these assays are restricted to
individual steps of the autophagic pathway and do not
allow for concurrent monitoring of multiple steps within
the autophagic/endolysosomal process.
A robust screen must identify compounds that specifi-
cally target the events within the autophagic or endoly-
sosomal pathway, as they share many common cellular
regulatory mechanisms [12]. In addition, it is of interest
to compare relative drug effects obtained under different
settings, including conditions, time points, and concen-
trations. Here, we sought to identify the impact of
compounds on autophagic activity using fluorescent
protein-based sensors for autophagic and endolysosomal
activities. We used (i) GFP-LC3 [17] to quantify autoly-
sosome formation, (ii) mCherry-GFP-LC3 [18] (tandem-
LC3) to simultaneously monitor autolysosome formation
and degradation events, and (iii) GFP-Rab7 [19,20] as a
marker of general changes in endolysosomal activities.
As a screening platform we utilized flow cytometry,
which allows for multiparametric and quantitative detec-
tion with high sampling rates, and the generation of
results amenable to statistical analysis. Importantly, the
integration of multiple pathway sensors by flow cytome-
try allowed for the precise quantification of autophagic
flux without the need for lysosomal inhibitors. Auto-
mated sampling in 96-well plates was used for measur-
ing time-dependent changes in autophagic and
endolysosomal activities. Following pipeline validation,
using commonly used drug modulators of autophagy,
we screened the Prestwick Chemical Library (http://
www.prestwickchemical.com), consisting of 1,120 US
Food and Drug Administration (FDA)-approved com-
pounds, for modulators of autophagy. We demonstrate
that lysosomal-inhibitor independent, multiparametric
screening outperforms conventional autophagy assays,
and we identified and validated cardiac glycosides as
novel potent and specific enhancers of autophagic flux.
Results
Flow cytometry detection of autolysosome formation and
degradation using tandem-LC3 overcomes requirement
for lysosomal inhibitors to infer autophagic flux
Autophagic flux, that is, coupled autophagosome forma-
tion and degradation, can be inferred by comparing
levels of cytosolic LC3-I and autophagosome mem-
brane-bound LC3-II, in the absence and presence of
lysosomal inhibitor [21]. Detected LC3 levels are
referred to as steady state and cumulative, respectively.
Here, lysosomal turnover of LC3 is demonstrated by
western blot detection of LC3-I (cytosolic) and LC3-II
(autophagosomal membrane), in the presence and
absence of bafilomycin A1 (Baf), which deacidifies the
(auto)lysosomes thereby inhibiting degradation [22]
(Figure 1a). Nutrient deprivation (ND) conditions alone
resulted in decreased levels of LC3-I and LC3-II, and
addition of Baf increased LC3-I/II levels to a greater
extent under ND conditions compared to full medium
(FM). Notably, quantification of western blot data allows
calculation of flux, however, results are of low resolu-
tion, as indicated by high standard error of the mean
(SEM) (Figure 1a).
As an alternative approach, we sought to differentiate
between autolysosome formation and degradation steps
utilizing the difference in pH sensitivity between GFP and
mCherry in live cells [23]. When fused to the autophagic
marker LC3, GFP fluorescence is quenched upon fusion
between autophagosome and lysosome due to the low
lysosomal pH, while mCherry remains fluorescent until
degradation by lysosomal proteases [18,24]. Cells were sta-
bly transfected with tandem-LC3. In live cells, high-resolu-
t i o ni m a g i n gd e m o n s t r a t e dt h a ta t6h ,N Dc o n d i t i o n s
increased the levels of mCherry-positive autolysosomes
compared to FM control conditions, with few apparent
autophagosomes (mCherry-positive and GFP-positive; that
is, yellow) (Figure 1b). The addition of Baf here resulted in
the accumulation of colocalized GFP-positive and
mCherry-positive autophagosomes and autolysosomes
(yellow) (Figure 1b, i). These results indicate that autolyso-
some formation is rapid under both basal (FM) and
induced (ND) autophagy conditions, and highlights the
lack of phenotype using GFP-LC3 alone. However, high-
resolution imaging of tandem-LC3 revealed variability
between cells, that is, not all cells show the same level of
accumulated autolysosomes (Figure 1b, white arrows), as
described previously [25]. Moreover, imaging is restricted
to low sample numbers with manual selection of cells,
thus potentially skewing or failing to capture the variability
of responses within populations.
To overcome the disadvantages described above, we
utilized flow cytometry to quantify responses at the
population level, an approach used previously to quan-
tify autolysosome formation [26]. Changes to GFP and
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Page 2 of 15Figure 1 Quantitative detection of autophagosomal formation and degradation using flow cytometry. (a) Western blot analysis of wild-
type cells, exposed to full medium (FM) or nutrient deprivation (ND) ± bafilomycin A1 (Baf) for 6 h. Cell lysates were analyzed for microtubule-
associated protein 1 light chain 3 B (LC3) and b-actin. Quantified bands are expressed relative to FM. (b) Representative image of cells stably
expressing mCherry-green fluorescent protein (GFP)-LC3B (tandem-LC3), exposed to FM/ND medium for 6 h ± Baf. (b)i Fluorescent labeling of
autophagosomes using tandem-LC3 allows differentiation between autophagosomes, autolysosome formation and degradation. (c-f) Tandem-
LC3 cells were exposed to FM/ND ± Baf for 1 to 16 h and fluorescence intensities were analyzed by flow cytometry. Histograms represent
distribution of fluorescence intensities of GFP (c) or mCherry (e) after 6 h (upper rows) or 16 h (lower rows) (see Additional file 1 for histograms
of FM + Baf). Diagrams show mean fluorescence intensities (relative to fluorescence intensity under FM = 1) of GFP (d) and mCherry (f) after
exposure to FM or ND ± Baf for 1 to 16 h.
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Page 3 of 15mCherry fluorescence intensities (Figure 1b, i) were
detected in live cell populations, under either FM or ND
conditions for 6 and 16 h. Histograms show the distri-
bution of GFP (Figure 1c) and mCherry (Figure 1e)
fluorescence intensities, respectively. In response to ND,
GFP fluorescence intensity decreased to 80% after 6 h
and to less than 50% after 16 h of treatment. In con-
trast, mCherry fluorescence intensity decreased to
approximately 85% after 6 h and 80% after 16 h of treat-
ment. Baf was included to block lysosomal degradation
during both ND-induced autophagy (Figure 1c,e) and
basal autophagy (FM) (Additional file 1). At 6 h, Baf
maintained GFP and mCherry fluorescence intensity at
levels slightly less than under FM conditions. At 16 h,
Baf treatment resulted in both GFP and mCherry fluor-
escence intensities greater than under FM conditions.
Hence, our approach allowed for quantification of both
autolysosome formation and degradation in a highly
specific manner, indicated by the block of GFP/mCherry
turnover by addition of Baf.
We further quantified time-resolved changes of GFP
and mCherry fluorescence levels in response to FM or
ND ± Baf for 1 to 16 h (Figure 1d,f). Results are reported
as fold increase or fold decrease relative to the intensity
levels of basal FM steady-state autophagy conditions
(that is, assigning fluorescence intensity of FM = 1),
thereby reporting relative impact of different time points
and conditions. In response to ND, GFP fluorescence
intensity decreased in a linear manner over time
(Figure 1d), whereas the decrease of mCherry fluores-
cence intensity slowed down following the 6 h time point
(Figure 1f), indicating continuous vesicle fusion, with
lysosomal degradation as the limiting step in autophagy.
The decreases in both GFP-LC3 and mCherry-LC3 fluor-
escence intensities were significant after 1 h of exposure
to ND conditions, underlining the sensitivity of flow-
cytometry-based detection in contrast to western blotting
(Figure 1a). Notably, although degradation steps could be
efficiently blocked by addition of Baf, our assay does not
rely on addition of lysosomal inhibitors to infer autopha-
gic flux. Instead, the loss of GFP fluorescence intensity
reports autolysosome formation and mCherry fluores-
cence intensity corresponds to autolysosome degradation,
allowing direct readout of autophagic flux.
To exclude the possibility of proteasomal degradation
of tandem-LC3, we used the specific proteasome inhibi-
tor epoxomicin (Epox; 1 μM) under both FM and ND
conditions (Additional file 2; high-resolution images are
shown in Additional files 3 and 4). Under FM condi-
tions, inhibition of the proteasome slightly suppressed
GFP fluorescence at 1 to 5 h timepoints, indicating an
initial weak activation of autophagy. Prolonged treat-
ment (> 8 h) resulted in a detectable increase in GFP
fluorescence, indicating an inhibition of autolysosome
formation. No changes were detected for mCherry fluor-
escence, indicating that Epox did not impact autolyso-
some degradation. Importantly, under ND conditions,
Epox did not affect GFP or mCherry fluorescence from
1 to 6 h, indicating that inhibition of proteasomal activ-
ity had no effect on degradation of tandem-LC3 under
ND for the first 6 h. From timepoints 8 to 16 h GFP
and mCherry fluorescence was increased, indicating an
inhibitory effect of Epox on autophagic degradation.
Thus, quantification of tandem-LC3 turnover by flow
cytometry is specific for autophagic degradation, indi-
cated by sensitivity to Baf and insensitivity to Epox
treatment.
Flow cytometry detection of endolysosomal activity using
GFP-Rab7
The endolysosomal pathway is coupled to diverse cell
mechanisms, including endocytosis, signal specificity
and autophagy [12], as autophagosomes fuse with late
endosomes during autolysosomal maturation [9]. To
assess potential crosstalk between endolysosomal and
autophagic degradation, we sought to utilize GFP-Rab7
[19,20] as an indicator of general changes in the endoly-
sosomal degradative pathway. Through comparison of
tandem-LC3 and GFP-Rab7 readouts it was possible to
differentiate specific effects on the autophagic pathway
from general changes in the endolysosomal degradation
pathway. Analysis of GFP-Rab7 by high-resolution ima-
ging indicated that, similar to LC3, endolysosomal flux
can be inferred by comparing the number of Rab7 vesi-
cles in presence and absence of Baf (Figure 2a). Under
ND conditions low numbers of small GFP-Rab7 vesicles
are detected. In response to Baf, the cytoplasm filled
with larger GFP-Rab7 vesicles. Western blot analysis
confirmed that endogenous Rab7 turnover is Baf sensi-
tive under both FM and ND conditions (Figure 2b),
with higher turnover under ND conditions. We further
c o n f i r m e dt h es p e c i f i c i t yo fR a b 7f o rt h el a t ee n d o s o -
mal and lysosomal compartments by cotransfecting
stable GFP-Rab7 cells with either mCherry-Rab5 (early
endosomal marker) or Lamp1-red fluorescent protein
(RFP) (lysosomal marker). As expected, Rab7 localized
to the Lamp1-RFP-positive lysosomal, rather than to
the mCherry-Rab5 early endosomal compartments
(Additional file 5). Analogous to GFP-LC3, we mea-
sured the decrease of GFP-Rab7 fluorescence intensity
under FM and ND conditions (Figure 2c). ND
increased the loss of GFP fluorescence intensity in a
time-dependent manner, however with decreasing
turnover rates after 6 h of incubation (Figure 2d).
Similar to GFP-LC3, addition of Baf inhibited the
decrease in GFP-Rab7 fluorescence intensity, but was
not required to detect endolysosomal flux (Figure 2
and Additional file 1).
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Page 4 of 15In summary, flow cytometry detection of tandem-LC3
and GFP-Rab7 allows for detection of autophagic and
endolysosomal flux, respectively. Importantly, quantita-
tive flux measurements are determined without the need
for lysosomal inhibitors, as flux could be inferred by
comparing FM to ND conditions. Changes in fluores-
cence intensity of GFP-LC3, mCherry-LC3 and GFP-
Rab7 upon exposure to ND were already significant
after 1 h of incubation (P <0 . 0 5 ) .H o w e v e r ,t oa l l o w
detection of minor drug-induced effects, 6 h incubations
were utilized in subsequent experiments, as higher sig-
nificant responses were detected (P < 0.001 for FM vs
ND). Furthermore, normalization of responses allows for
relative comparison of autophagic and endolysosomal
responses, as well as condition-dependent and time-
dependent impacts.
Drug induction of autophagy differentially impacts
autophagic and endolysosomal activities under FM and
ND conditions
As a benchmark, we next examined the relative impact
of reported autophagy modulating compounds, under
conditions of basal and ND-induced autophagy (Figure
3). Values represent fold-change (for example, 0.10 =
10%) increase or decrease relative to either FM or ND
control measurements, depending on indicated condi-
tion. An important consideration to the use of fluores-
cent proteins is the impact of cellular pH levels, protein
synthesis, and compound autofluorescence. Thus, to
compensate for non-specific changes to fluorescence
intensities, experiments were performed under identical
conditions in cells stably expressing control (Ctr)-tan-
dem or Ctr-GFP. Depending on the stimulus, fluores-
cence intensities varied by up to 7% (results not shown).
By correcting each data point for either tandem-LC3 or
GFP-Rab7 to the respective control value, changes unre-
lated to autophagy were minimized (see Materials and
methods for details). Although we report changes in
fluorescence intensity of both GFP/mCherry, the corre-
sponding ratio provided no additional insight, as differ-
ences cannot be captured (for example, simultaneous
increase in GFP/mCherry, see Additional file 6).
Cells were treated with autophagy inducers rapamycin
(inhibitor of mTOR; 0.1 μM) [27], AICAR (activator of
AMPK; 200 μM) [28,29] or resveratrol (100 μM) [30]
under either FM or ND conditions for 6 h. In addition,
we tested the effect of three widely used autophagy inhi-
bitors: Baf (0.1 μM), inhibiting lysosomal function, and
wortmannin (WM; 2.3 μM) [31] and 3-methyladenine(3-
M A ;5m M )[ 3 2 ] ,t w op h o s p h o i n o s i t o l3( P I 3 )k i n a s e
inhibitors which inhibit autophagy induction. See Addi-
tional files for high-resolution images of the respective
drugs under FM (Additional file 3) and ND (Additional
file 4) conditions, in presence and absence of Baf.
Rapamycin and resveratrol both induced a significant
increase in autophagic activity compared to FM (Figure
3a). Notably, under FM conditions, resveratrol enhanced
autolysosomal degradation to levels greater than induced
by ND conditions. AICAR, which by activating AMPK
Figure 2 Quantitative detection of endolysosomal activity
using flow cytometry. (a) Representative image of green
fluorescent protein (GFP)-Rab7 cells, exposed to full medium (FM) or
nutrient deprivation (ND) medium for 6 h ± bafilomycin A1 (Baf).
(b) Western blot analysis of wild-type cells, exposed to FM or ND ±
Baf for 6 h. Cell lysates were analyzed for Rab7 and b-actin. (c)
Histograms show distribution of GFP-Rab7 fluorescence intensity
after 6 h (upper row) or 16 h (lower row) incubation with FM or ND
± Baf. (d) Diagram represents mean fluorescence intensity (relative
to fluorescence intensity under FM = 1) of GFP-Rab7 for 1 to 16 h
incubation with FM/ND ± Baf.
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Page 5 of 15inhibits mTOR [33], had no significant effect on autoly-
sosome fusion or degradation. Similar to FM conditions,
resveratrol further increased both autolysosome forma-
tion and degradation under ND conditions, with a more
pronounced enhancing effect on autolysosomal degrada-
tion (Figure 3b). In contrast to FM conditions, rapamy-
cin decreased both autolysosome formation and
degradation under ND conditions. Rapamycin signifi-
cantly increased endolysosomal flux under FM condi-
tions, even above ND induced turnover (Figure 3c).
However, rapamycin had no significant effect on endoly-
sosomal activity under ND conditions (Figure 3d), indi-
cating differential regulation for FM and ND conditions.
Both AICAR and resveratrol had no significant effect on
endolysosomal turnover (Figure 3c,d).
Notably, Baf was the only compound inhibiting autoly-
sosomal formation and degradation events and endoly-
sosomal turnover under both FM and ND conditions
(Figure 3). Under FM conditions, WM and 3-MA had
no inhibitory effect on autophagy, with 3-MA even
slightly increasing formation of autolysosomes (Figure
3a). In contrast, both WM and 3-MA inhibited autolyso-
some formation and degradation under ND conditions,
with WM being more efficient (Figure 3b). 3-MA also
upregulated endolysosomal turnover under FM but had
no effect under ND conditions (Figure 3c,d). In contrast,
WM had no effects under FM, while inhibiting endoly-
sosomal turnover under ND conditions, even more effi-
ciently than Baf (Figure 3c,d). This indicates WM to be
am o r es p e c i f i ca n dp o t e n ti n h i b i t o rt h a n3 - M Aw i t h
respect to both autophagic and endolysosomal activity.
High-content flow cytometry to identify small compounds
enhancing basal autophagic flux
Defective autophagy is implicated in many diseases [1],
and therefore the identification of drugs specifically
modulating autophagic flux, without interfering with
other endolysosomal processes, is of great translational
interest. To that end, we modified the above workflow
to screen the Prestwick Chemical Library, consisting of
1,120 FDA-approved compounds, for modulators of
autophagy (Additional file 7).
Using the 96-well plate format, drug impact was
determined by measuring GFP-LC3 fluorescence inten-
sity under basal (FM) autophagy conditions (Figure 4a).
GFP-LC3 was used as a primary readout, since either
upregulation or downregulation in autophagic activity
would first be manifested in changed fluorescence inten-
sity levels of GFP-LC3. Possible effects downstream of
autolysosome formation are then identified in a second-
ary screen, using tandem-LC3 and GFP-Rab7 reporters,
as well as LysoTracker Red (LTR) to assess lysosomal
activity. Cells were incubated with drugs (10 μg/ml) in
FM for 6 h. This early time point was determined
Figure 3 Impact of autophagic regulators on autophagosomal
fusion/degradation and endolysosomal turnover. mCherry-green
fluorescent protein (GFP) (tandem)-microtubule-associated protein 1
light chain 3 B (LC3) (a,b) or GFP-Rab7 (c,d) cells were exposed to
either full medium (FM) (a,c) or nutrient deprivation (ND) (b,d)
conditions ± respective drugs (rapamycin, 0.1 μM; AICAR, 200 μM;
resveratrol, 100 μM; bafilomycin A1 (Baf), 0.1 μM; wortmannin (WM),
2.3 μM; 3-MA, 5 mM) for 6 h. Fluorescence intensities of tandem-
LC3/GFP-Rab7 were detected by flow cytometry. Data was
normalized as described in Materials and methods (including
normalization to control (Ctr) constructs). Values represent fold
changes in relation to the respective control condition (FM for (a,c)
and ND for (b,d)). *P < 0.05, **P < 0.01, ***P < 0.001.
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increasing the risk of long-term impacts, such as sec-
ondary effects influencing global autophagy or protein
levels. Based on changes to GFP-LC3 fluorescence
intensity we identified 38 potential inducers and 36
potential inhibitors of autolysosomal formation (Figure
4b), with a threshold applied at mean ± s. Among these
hits were compounds previously reported as regulators
of autophagy, including autophagy inducers resveratrol
[30] and camptothecin [34], as well as autophagy inhibi-
tors colchicine [35] and quinacrine [36] (Figure 4b).
Discovery and validation of cardiac glycosides as potent
activators of autophagic activity
Remarkably, the 38 potential enhancers of autophagy
included all of the 8 cardiac glycosides present in the
Prestwick Chemical Library. Cardiac glycosides are com-
monly used in the clinical treatment of various heart
conditions [37] and have recently emerged as potential
cancer therapeutics [38]. Therefore, we selected the
three most potent cardiac glycosides with clinical rele-
vance (digoxin, strophanthidin, and digoxigenin) for
validation and concentration-dependent analysis by
measuring their effect on tandem-LC3, GFP-Rab7 and
LTR (see Additional file 8 for concentration dependent
analysis of additional primary hits).
Drugs were retested at concentrations of 10 μg/ml, 1
μg/ml, 100 ng/ml and 10 ng/ml (Figure 5). Strophanthi-
din and digoxigenin induced autolysosome formation
(loss in GFP fluorescence of tandem-LC3) at concentra-
tions ranging from 10 μg/ml to 100 ng/ml; however,
autolysosomal degradation (loss in mCherry fluores-
cence of tandem-LC3) was induced only at concentra-
tions from 1 μg/ml to 100 ng/ml. Digoxin induced both
autolysosome formation and degradation at concentra-
tions ranging from 10 μg/ml to 10 ng/ml. At 10 μg/ml
all drugs induced increased lysosomal activity (LTR),
with digoxin additionally upregulating endolysosomal
turnover (enhanced loss of GFP-Rab7 fluorescence). At
100 ng/ml no drug had a significant effect on endolyso-
somal turnover or lysosomal activity. Notably, although
at higher concentrations strophanthidin and digoxigenin
had a greater effect on autolysosome formation, autoly-
sosome degradation rates were maximal with 100 ng/ml.
Digoxin at 100 ng/ml maximally induced both formation
and degradation of autolysosomes, indicating efficient
enhancement of autophagic degradation. It is of clinical
interest that at these concentrations, digoxin has been
previously shown to induce apoptosis specifically in can-
cer cells and comparable concentrations can be found in
plasma of cardiac patients [39].
We further confirmed the induction of autophagic flux
by high-resolution microscopy and western blotting. At
100 ng/ml digoxin, strophanthidin, and digoxigenin all
increased the Baf-dependent accumulation of GFP-LC3-
positive autophagosomes compared to control condi-
tions (Figure 6a). Likewise, all drugs increased the turn-
over of endogenous LC3-I and LC3-II as revealed under
Baf treatment (Figure 6b). All approaches identified
digoxin as the more potent inducer of autophagy than
strophanthidin and digoxigenin.
Discussion
Autophagy is of a highly dynamic nature and its interac-
tions with the endolysosomal pathway are complex
[9-12]. Therefore, analysis of autophagic activity requires
detection of multiple pathway activities, including autop-
hagosome formation and degradation, endolysosomal
turnover and lysosomal degradative capacity. Here, we
applied automated flow cytometry to quantitatively mea-
sure temporal, conditional, and drug-induced impacts on
each of these individual steps. Key to our approach was
the population sampling of single live cells, which gener-
ated multiparametric datasets amenable to statistical ana-
lysis. Specifically, single cell discrimination of pH
quenching of GFP fluorescence of tandem-LC3 reported
autolysosome formation, while loss of mCherry fluores-
cence of tandem-LC3 reported autolysosomal degrada-
t i o n .B yc o m p a r i n gG F Pa n dm C h e r r yf l u o r e s c e n c e
intensities to the respective control conditions, autopha-
gic flux was inferred without the need for lysosomal inhi-
bitors (Figure 1). Furthermore, we established GFP-Rab7
turnover as a robust indicator for general changes in
endolysosomal activity (Figure 2), allowing for the dis-
tinction between specific autophagic and general endoly-
sosomal activity. Mean fluorescence intensities were
sampled for both tandem-LC3 and GFP-Rab7, and out-
performed western blot quantification in terms of sensi-
tivity and accuracy (Figures 1 and 2). Thereby, our assay
allows for comparison of multiple autophagy parameters,
with respect to concentration, temporal, and conditional
dependencies. Moreover, by using CMV promoter based
reporter systems and normalization steps (Ctr-tandem/
Ctr-GFP), we further assure the specificity of this
approach to quantify autophagic activity independent of
transcriptional or drug-induced off-target effects.
Overall, combining multiparametric flow cytometry
with high-content markers for autolysosomal degrada-
tion pathways improves standard screening methods
[14-16] due to reduced risk of potential off-target effects
by the addition of lysosomal inhibitors. Moreover, our
approach outperforms current flow-cytometry-based
autophagy assays [26,40] through quantification of both
autolysosomal formation and degradation as well as cap-
turing changes in the endolysosomal pathway. The abil-
ity of our assay to facilitate the identification of specific
regulators of autophagy is highlighted by the drug-speci-
fic chart of activities of different autophagic steps,
Hundeshagen et al. BMC Biology 2011, 9:38
http://www.biomedcentral.com/1741-7007/9/38
Page 7 of 15Figure 4 Identification of potential activator and inhibitor of autophagy. (a) Distribution of compounds. Fluorescence intensities are
expressed relative to full medium (FM) conditions (fluorescence intensity under FM = 1). Each plate contained nutrient deprivation (ND) medium
(relative fluorescence intensity = 0.55) and rapamycin (relative fluorescence intensity = 0.71) as positive and bafilomycin A1 (Baf) (relative
fluorescence = 1.37) as negative controls. Compounds were considered as hits if fluorescence intensities were higher/lower than mean ± s. (b)
Primary hits identified by flow cytometry based autophagy screen. Autophagy inducers/inhibitors were grouped into respective classes. Color
labeling (green/red) represents previously reported cardioprotective/cardiotoxic effects. Previously reported anti-cancer properties are indicated
by filled squares. Respective PubMed database identification numbers (PMIDs) can be found in Additional file 9.
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Page 8 of 15obtained by individually monitoring the involved autoly-
sosomal degradation pathways (Figure 7). The impor-
tance of such an approach was apparent in our initial
benchmark where we analyzed compounds that are
widely used to inhibit and activate autophagy. We tested
the effect of these compounds under conditions of both
basal (FM) and activated (ND) autophagy. Activation of
AMPK by AICAR had no effect on autophagy. This is in
line with previous studies, reporting AMPK-independent
effects of AICAR that block autophagy [41,42].
Strikingly, we found that drug impact can be strongly
dependent on the underlying condition, with drugs
having opposing effects if applied under FM or ND con-
ditions. Rapamycin (Figure 3), commonly applied to
induce autophagy [27], enhanced autophagy under FM,
but had a surprising inhibitory effect under ND condi-
tions. ND is well established to strongly inhibit mTOR
[43]. Thus, the addition of rapamycin under ND condi-
tions may not lead to additional mTOR inhibition, but
instead inhibit autophagy by non-specific effects. Indeed,
a previous report suggested mTOR independent inhibi-
tory effects on autophagy for increased concentrations of
rapamycin (> 250 nM) [16]. In contrast, 3-MA (Figure 3),
commonly used as an autophagy inhibitor [32], decreased
Figure 5 Cardiac glycosides are novel and specific inducer of autophagic flux. Diagrams showing autophagic activity (upper row),
endolysosomal turnover (middle row) and lysosomal activity (bottom row), determined by flow cytometric quantification of fluorescence
intensities of mCherry-green fluorescent protein (GFP) (tandem)-microtubule-associated protein 1 light chain 3 B (LC3), GFP-Rab7 and LysoTracker
Red (LTR), respectively. Data was normalized as described in Materials and methods (including normalization to control (Ctr) constructs). Values
represent fold changes in relation to full medium (FM) control condition. Drugs have been used at indicated concentrations under FM for 6 h.
*P < 0.05, **P < 0.01, ***P < 0.001.
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Page 9 of 15Figure 6 Confirmation of autophagic flux induction by cardiac glycosides. (a) Representative images of mCherry-green fluorescent protein
(GFP)-microtubule-associated protein 1 light chain 3 B (LC3) cells; exposed to full medium (FM), nutrient deprivation (ND), FM + digoxin,
strophanthidin or digoxigenin (each at 100 ng/ml) in presence/absence of bafilomycin A1 (Baf) for 6 h. (c) Wild-type cells were incubated with
FM, ND, FM + digoxin, strophanthidin or digoxigenin (each at 100 ng/ml) in presence/absence of Baf for 6 h. Cell lysates were analyzed for LC3
and b-actin levels by western blotting.
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Page 10 of 15ND-induced autophagy, but activated autophagy if
applied under FM conditions. Autophagy is regulated
by two PI3Ks; while class III PI3K is required for the
induction of autophagy, class I PI3K negatively regu-
lates autophagy. Depending on the condition, inhibi-
tion of PI3K by WM or 3-MA might therefore have
either inhibitory or activating effects [44]. Furthermore,
our results suggest both negative and positive regula-
tion of endolysosomal activity by PI3K, similar to
autophagic regulation. Thus, the sensitivity of our
approach allows for the comparison of condition-
dependent and relative potencies of autophagy modula-
tors. Here, we showed condition-dependent effects of
rapamycin and identified Baf as the most potent inhi-
bitor under both FM and ND, followed by WM being
more specific and potent than 3-MA.
We subsequently identified novel modulators of
autophagy by screening 1,120 FDA approved, bioactive
small compounds (Figure 4), demonstrating the transla-
tional potential of our approach. GFP-LC3 was used as
a primary readout for autolysosome formation in live
cells, as previously described by Shvets et al.[ 2 6 ] .
Selected hits were then subjected to detailed analysis by
monitoring effects on tandem-LC3, GFP-Rab7, and LTR.
Thereby, we were able to identify defects downstream of
autolysosome formation and confirm specific induction
of the autophagic degradation pathway.
Applying this workflow, about 3% of screened com-
pounds were classified as potential activators and 3% as
potential inhibitors of autophagy (Figure 4b). Some of
these hits have previously been reported as autophagic
regulators, including resveratrol [30], camptothecin [34],
colchicine [35] and quinacrine [36], demonstrating the
accuracy of our approach for compound screening.
Strikingly, the novel hits of our screen contained a
family of eight compounds, cardiac glycosides, which are
commonly used to treat heart failure [37] and more
recently as cancer therapeutics [38]. These findings
demonstrate the potential of high-content autophagy
screening for identifying dual-purpose compounds with
the goal of minimizing damage to essential, non-prolif-
erating cells, while targeting proliferating cancer cells.
For three cardiac glycosides, digoxin, strophanthidin and
digoxigenin, we determined the optimal concentrations
to specifically induce autolysosome formation and
degradation, without affecting general endolysosomal
activity (Figure 5). We further confirmed activation of
autophagy by western blotting and imaging approaches
(Figure 6). Cardiac glycosides are known to inhibit Na
+-K
+-ATPases [38], leading to increased calcium levels
and thereby giving a possible mechanism for their effect
on autophagy. Calcium can upregulate autophagy
[21,45] and modulators of calcium are prominent
among compounds identified in other autophagy screens
[14,15,46]. Cardiac glycosides have been suggested for
cancer therapy, due to their potential to induce tumor
specific cell death [38]. It is remarkable that many of
the identified autophagy activators have both anti-cancer
and cardioprotective properties (Figure 4b and Addi-
tional file 9), indicating potential drugability of autopha-
gic cell death-associated mechanisms. Conversely, many
of the reported autophagy inhibitors induce cardiotoxi-
city and have anti-cancer properties. The role of autop-
hagy inhibition in the efficiency of cell death induction
during chemotherapy warrants further study [47]. Our
study demonstrates the suitability of high-content
screening for the characterization of localized-drug
impact on autophagy. Future work might employ indu-
cible expression systems, potentially also including addi-
tional sensors, such as GFP-p62 [48], thereby further
increasing the sensitivity of our approach and facilitating
the portability to other cell types.
Conclusions
In summary, we present a multiparametric screening
approach, validated against common imaging and bio-
chemical assays, which allows for quantitative measure-
ments of the entire autolysosomal pathway, independent
of lysosomal inhibitors. The ability to measure relative
impacts on different pathway events revealed striking
conditional differences between the most commonly
used drug modulators of autophagy. In addition, this
approach was highly scalable, allowing for quantitative
drug screening of 1,120 small compounds. From within
a total number of 74 hits, cardiac glycosides were identi-
fied and 3 were further validated as novel inducers of
autophagy. Thus high content autophagy screening is
Figure 7 Drug profiling by multiparametric quantitative
analysis of autolysosomal degradation pathways. Figure shows
parameters for autolysosomal degradation pathways obtained by
flow cytometry based screening of green fluorescent protein (GFP)-
Rab7, GFP/mCherry (of mCherry-GFP (tandem)-microtubule-
associated protein 1 light chain 3 B (LC3)) and LysoTracker Red
(LTR).
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Page 11 of 15effective for identifying drugs of interest for highly rele-
vant disease type and thereby suggesting clear treatment
strategies for in vivo confirmation.
Methods
Cell culture
MCF-7 breast cancer cells (Cell Lines Services, Heidel-
berg, Germany) were cultivated in FM, consisting of
Dulbecco’s modified Eagle medium (DMEM) (Invitro-
gen, Karlsruhe, Germany) supplemented with 10% fetal
calf serum, non-essential amino acids, Glutamax (Invi-
trogen) and penicillin/streptomycin/amphotericin, at 37°
Cw i t h5 %C O 2. Stable cell lines (GFP-LC3, tandem-
LC3, GFP-Rab, GFP and mCherry-GFP), were generated
via transfection (Effectene; Qiagen, Hilden, Germany)
with the respective construct and selection through
addition of G418 (Invitrogen) at 500 μg/ml. Single cell
colonies were selected and stable cell lines were cultured
i nt h ep r e s e n c eo f1 0 0μg/ml G418. Transient transfec-
tion (mCherry-Rab5 and Lamp1-RFP) was carried out
with Effectene (Qiagen). Cells were incubated in full
medium (FM) or nutrient deprivation (ND) conditions
as indicated. Cells were exposed to ND conditions by
replacing FM with modified Krebs-Henseleit balanced
salt solution (110 mM NaCl, 4.7 mM KCl, 1.2 mM
KH2PO4,1 . 2 5m MM g S O 4, 1.2 mM CaCl2,2 5m M
NaHCO3, 15 mM glucose, 20 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), pH 7.4).
Construction of expression vectors
To generate mCherry-GFP-LC3B, LCB3 CDS was ampli-
fied from pEGFP-LC3 [24] inserted into pmCherry-C1.
Subsequently enhanced GFP (EGFP) was inserted, in
frame, between mCherry and LC3B. Rab5a (DKFZ clone
repository, NM_004162) was amplified and inserted into
pmCherry-C1 to generate mCherry-Rab5.
Flow cytometry
Cells were cultured in 96-well plates at a density of
25,000 cells/well. For flow cytometric analysis, culture
medium was removed and cells were incubated in 50 μl
Trypsin-ethylenediaminetetraacetic acid (EDTA) (Invi-
trogen) for 5 min. Trypsin was inactivated by addition of
150 μl of ice-cold Krebs-Henseleit with 1% bovine serum
albumin (Sigma-Aldrich, Munich, Germany). Flow cyto-
metric analysis was carried out with a modified Beck-
man-Coulter (Krefeld, Germany) FC500MPL, allowing
direct sampling from 96-well plates and simultaneous
excitation and detection of green (488 nm) and red (561
nm) fluorescent proteins. At least 1,000 events were col-
lected for each well. Color compensation was carried out
for multicolor detection using matched single fluorescent
proteins compensation controls. To minimize non-speci-
fic compound effects, each experiment was carried out in
parallel with both the sensor construct and the respective
fluorescent protein alone, that is, mCherry-GFP (Ctr-tan-
dem) or GFP (Ctr-GFP). For each sample, cell number
and mean fluorescence intensity were reported. All mea-
surements were normalized to FM conditions and then
corrected for unspecific changes by normalization to
respective Ctr constructs, measured under identical con-
ditions. The mean of the normalized values was
expressed as fold changes to either FM or ND, as indi-
cated. Positive values indicate activation and negative
values indicate inhibition. Each experiment was carried
out at least three times independently.
For staining of lysosomes, cells were incubated with
LTR (Invitrogen) at a concentration of 50 nM for the
last 30 min of treatment, washed once with the respec-
tive medium and then processed for analysis.
Small compound screen
Stable GFP-LC3 cells were incubated with small com-
pounds of the Prestwick Chemical library (Prestwick
Chemical, Illkirch, France) at a concentration of 10 μg/
ml in FM for 6 h. Rapamycin (0.1 μM) and ND were
used as positive controls, and Baf (0.1 μM) as negative
control. Controls were randomly distributed over first/
last column and controlled for edge effects. Analysis by
flow cytometry was carried out as described above. Each
experiment was carried out in duplicate and compounds
were excluded if duplicates differed more than 10%.
Reagents
Bafilomycin A1 (Baf), rapamycin, wortmannin (WM), 3-
MA, AICAR, resveratrol, and epoxomicin were pur-
chased from Calbiochem (Darmstadt, Germany).
Digoxin, digoxigenin, strophanthidin, doxorubicin, dau-
norubicin and mitoxantrone were purchased from
Sigma-Aldrich. Drugs were diluted in dimethylsulfoxide
(DMSO).
Statistical analysis
Statistical significance was determined using a one-tailed
Student’s t test. Values are expressed as mean ± SEM.
Microscopy
Cells were grown on iBidi 8-well slides (40,000 cells/
well) and treated as indicated. High-content imaging
was carried out using a DeltaVision RT deconvolution
microscope (Applied Precision, Issaquah, WA, USA)
equipped with a 60 × oil immersion objectives and a
CCD digital camera (Hamamatsu, Herrsching, Ger-
many). Images were deconvolved to maximize spatial
resolution and processed using ImageJ software [49].
Images shown are maximum projections of Z stacks of
representative cells (selected from at least three inde-
pendent experiments).
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Cells were cultured in 6-well plates (400,000 cells/well)
and treated as indicated. After indicated time points,
whole cell lysates were prepared with radioimmunopre-
cipitation assay (RIPA) lysis buffer (Upstate, Charlottes-
ville, VA, USA) containing Protease Inhibitor Cocktail
(Roche, Mannheim, Germany). Protein concentrations
were measured by Coomassie assay (Sigma-Aldrich),
adjusted to obtain equal loading and mixed with NuPage
sample buffer master mix (NuPage LDS buffer and
reducing reagent, Invitrogen). Samples were then sepa-
rated on 12% NuPage Bis-Tris gels (Invitrogen) and
transferred to nitrocellulose membranes using the iBlot
dry blotting system (Invitrogen). Immunodetection was
carried out using primary antibodies against b-actin
( A b c a m ,C a m b r i d g e ,U K ) ,L C 3 B( C e l lS i g n a l i n g ,D a n -
vers, MA, USA), and Rab7 (Cell Signaling). Membranes
were prepared with horseradish peroxidase (HRP)-linked
secondary antibodies (Cell Signaling) and chemilumines-
cence was detected using a Chemiluminescence Detec-
tion System (Intas, Göttingen, Germany). Immunoblots
shown are representative of at least three independent
experiments. Quantification of immunoblots (Figure 1a)
was performed on three independent samples using
ImageJ software [49]. Intensity of respective bands
(LC3-II) were quantified and normalized to the loading
control (b-actin).
Additional material
Additional file 1: Histograms of mCherry-green fluorescent protein
(GFP) (tandem)-microtubule-associated protein 1 light chain 3 B
(LC3) and GFP-Rab7 measurements. Tandem-LC3 (a,b) or GFP-Rab7 (c)
cells were exposed to full medium (FM), nutrient deprivation (ND) or FM
+ bafilomycin A1 (Baf) conditions and fluorescence intensities were
analyzed by flow cytometry. Histograms represent distribution of
fluorescence intensities of GFP (a) or mCherry (b) of tandem-LC3 and
GFP-Rab7 (c) after 6 h (upper rows) or 16 h (lower rows) incubation with
FM, ND or FM + Baf.
Additional file 2: Effect of proteasomal inhibition on degradation of
mCherry-green fluorescent protein (GFP) (tandem)-microtubule-
associated protein 1 light chain 3 B (LC3). Tandem-LC3 cells were
exposed to full medium (FM)/nutrient deprivation (ND) ± epoxomicin
(Epox; 1 μM) for 1 to 16 h and fluorescence intensities were analyzed by
flow cytometry. Diagrams show mean fluorescence intensities (relative to
fluorescence intensity under FM = 1) of GFP (a) and mCherry (b) after
exposure to FM or ND ± Epox for 1 to 16 h.
Additional file 3: Effect of autophagic regulators on localization of
mCherry-green fluorescent protein (GFP) (tandem)-microtubule-
associated protein 1 light chain 3 B (LC3) under full medium (FM)
conditions. Representative images of cells stably expressing tandem-LC3.
Cells were exposed to FM and respective autophagy regulators in
presence/absence of bafilomycin A1 (Baf) for 6 h.
Additional file 4: Effect of autophagic regulators on localization of
mCherry-green fluorescent protein (GFP) (tandem)-microtubule-
associated protein 1 light chain 3 B (LC3) under nutrient deprivation
(ND) conditions. Representative images of cells stably expressing
tandem-LC3. Cells were exposed to ND and respective autophagy
regulators in presence/absence of bafilomycin A1 (Baf) for 6 h.
Additional file 5: Rab7 is a specific marker for late endosomal/
lysosomal compartments. Representative images of stable Rab7-green
fluorescent protein (GFP) cells, cotransfected with Lamp1-red fluorescent
protein (RFP) (a) or mCherry-Rab5 (b). Cells were exposed to full
medium (FM) or nutrient deprivation (ND) ± bafilomycin A1 (Baf) for 6 h.
Additional file 6: Ratio of green fluorescent protein (GFP)/mCherry
of mCherry-GFP (tandem)-microtubule-associated protein 1 light
chain 3 B (LC3). Ratio of relative fluorescence intensities of GFP/mCherry
(of tandem-LC3), as determined in Figure 3.
Additional file 7: Screening approach for novel regulators of
autophagic activity. Green fluorescent protein (GFP)-microtubule-
associated protein 1 light chain 3 B (LC3) cells were plated in 96-well
format and incubated in full medium (FM) with small compounds (10
μg/ml) for 6 h. Experiments were carried out in duplicates and cells were
analyzed by flow cytometry for fluorescence intensities of GFP-LC3.
Selected hits were then run through secondary analysis by
multiparametric analysis of lysosomal degradation pathways,
quantification of mCherry-GFP (tandem)-LC3, GFP-Rab7 (including
normalization to control (Ctr) constructs) and LysoTracker Red (LTR) at
various concentrations. Hits were validated by biochemical/imaging
analysis.
Additional file 8: Concentration-dependent effects of anthracyclines
on autolysosomal degradation pathways. Diagrams showing autophagic
activity (upper row), endolysosomal turnover (middle row) and lysosomal
activity (bottom row), determined by flow cytometric quantification of
fluorescence intensities of mCherry-green fluorescent protein (GFP)
(tandem)-microtubule-associated protein 1 light chain 3 B (LC3), GFP-Rab7
and LysoTracker Red (LTR), respectively. Data was normalized as described
in Materials and methods (including normalization to control (Ctr)
constructs). Values represent fold-changes in relation to full medium (FM)
control condition. Drugs have been used at indicated concentrations under
FM for 6 h. *P <0 . 0 5 ,* * P < 0.01, ***P <0 . 0 0 1 .
Additional file 9: List of compounds classified as hits by primary
screen. PubMed database identification numbers (PMIDs) of previously
reported cardioprotective/cardiotoxic effects and anti-cancer properties
as stated in Figure 4.
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